Sage Journals: Discover world-class research

Abstract

Hyperglycemia after aneurysmal subarachnoid hemorrhage (aSAH) occurs frequently and is associated with delayed cerebral ischemia (DCI) and poor clinical outcome. In this review, we highlight the mechanisms that cause hyperglycemia after aSAH, and we discuss how hyperglycemia may contribute to poor clinical outcome in these patients. As hyperglycemia is potentially modifiable with intensive insulin therapy (IIT), we systematically reviewed the literature on IIT in aSAH patients. In these patients, IIT seems to be difficult to achieve in terms of lowering blood glucose levels substantially without an increased risk of (serious) hypoglycemia. Therefore, before initiating a large-scale randomized trial to investigate the clinical benefit of IIT, phase II studies, possibly with the help of cerebral blood glucose monitoring by microdialysis, will first have to improve this therapy in terms of both safety and adequacy.

Keywords

diabetes mellitus vasospasm glucose hyperglycemia hypoglycemia subarachnoid hemorrhage

Introduction

Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating disease with high case morbidity and case fatality rates (van Gijn et al, 2007). Although these rates have decreased in the last decades, still 35% of aSAH patients die within the first month after the hemorrhage (Nieuwkamp et al, 2009). Prevention and treatment of neurologic complications such as rebleeding, hydrocephalus, and delayed cerebral ischemia (DCI) are obvious targets to improve prognosis. Besides neurologic complications, patients with aSAH often have cardiopulmonary and general medical complications that can influence outcome. Hyperglycemia in aSAH patients is common and associated with poor clinical outcome (Badjatia et al, 2005; Charpentier et al, 1999; Dorhout Mees et al, 2003; Frontera et al, 2006; Kruyt et al, 2008, 2009; Lanzino et al, 1993). As treatment for hyperglycemia is available, it has attracted increasing attention as a target for intervention, although adequate and safe glycemic control is difficult to achieve in patients with aSAH.

As hyperglycemia seems to be implicated in the pathway from aSAH to poor clinical outcome, insight into these mechanisms may reveal new treatment options. We undertook a nonsystematic literature search to provide an overview of the potential causes and consequences of hyperglycemia in aSAH patients and to address the pathophysiological mechanisms that might link hyperglycemia to poor clinical outcome. Furthermore, we performed a systematic literature search to review studies on glycemic control in aSAH patients. Finally, we provide directions for further trials and clinical management concerning glycemic control in this patient group.

Mechanisms Leading to Hyperglycemia After Aneurysmal Subarachnoid Hemorrhage

In patients admitted within 72 hours from aSAH, mean admission glucose is around 9 mmol/L, and around 3 out of 4 patients with aSAH are hyperglycemic on admission (Kruyt et al, 2009). Studies that report on glucose levels during the first 1 or 2 weeks of the clinical course report that hyperglycemia persists with levels exceeding 7 to 8mmol/L (Badjatia et al, 2005; Dorhout Mees et al, 2003; Frontera et al, 2006; Kruyt et al, 2008; Lanzino et al, 1993).

In ischemic stroke, hyperglycemia on admission is also frequent (Capes et al, 2001). This is, at least in part, attributed to (unrecognized) abnormalities of glucose metabolism such as diabetes mellitus (DM) that was existent before the stroke in around one third of patients (Gray et al, 2004; Kernan et al, 2005; Vancheri et al, 2005). As DM is not a risk factor for aSAH (Adams Jr et al, 1984; Feigin et al, 2005) and as patients with SAH are relatively young, the proportion of aSAH patients with preexistent abnormalities of glucose metabolism is much smaller than in patients with ischemic stroke.

There are several explanations for the increased glucose levels in acute aSAH patients. First, aSAH is accompanied by the activation of the hypothalamic–pituitary–adrenal axis and the activation of the sympathetic autonomic nervous system (Gauna et al, 2005). This activation results in an increase in the levels of stress hormones such as cortisol and catecholamines up to day 10 after the aSAH (Naredi et al, 2000; Vergouwen et al, 2010). These hormones enhance glycogenolysis, gluconeogenesis, proteolysis, and lipolysis, all resulting in excessive glucose production (Barth et al, 2007; Seematter et al, 2004). Moreover, catecholamines inhibit glucose transport by inhibition of insulin binding, resulting in insulin resistance with hyperinsulinemia (Gearhart and Parbhoo, 2006; Hunt and Ivy, 2002). Indeed, increased levels of cortisol are associated with increased levels of blood glucose in aSAH patients (Vergouwen et al, 2010). Second, aSAH is accompanied by an increased inflammatory response with release of cytokines (Hendryk et al, 2004). Cytokines, in turn, have been linked directly to hyperglycemia and insulin resistance (Hendryk et al, 2004; Hotamisligil and Spiegelman, 1994; Plomgaard et al, 2005; Rask-Madsen et al, 2003). In addition, cytokines stimulate the hypothalamic–pituitary–adrenal axis, further increasing the stress response. Interestingly, an altered glucose metabolism and hyperglycemia can in turn also stimulate the inflammatory response, raising the question of what is the cause and what is the effect (Esposito et al, 2002).

Third, besides a central role in the stress reaction, the hypothalamus also has an important role in maintaining glucose homeostasis by reducing hepatic gluconeogenesis and increasing insulin sensitivity (Obici et al, 2002; Schwartz and Porte, 2005). Neuropathological studies show that the majority of acute aSAH patients have hypothalamic lesions (Crompton, 1963). Moreover, a recent study reported hypothalamic dysfunction in the acute phase of aSAH (Klose et al, 2010), whereas the same study could not confirm earlier findings of hypothalamic dysfunction at longer (years) follow-up (Klose et al, 2010; Schneider et al, 2007). Whether acute hypothalamic dysfunction indeed contributes to hyperglycemia in aSAH patients is currently unclear.

In conclusion, increased stress and inflammatory responses seem to be the most important contributors to hyperglycemia after aSAH. Preexistent abnormalities of glucose metabolism do not seem to have a prominent role in aSAH patients, and the role of hypothalamic dysfunction and impaired glucose homeostasis remains uncertain (Figure 1, upper panel).

Figure 1

Figure with hypothetical mechanisms: leading to insulin resistance in patients with aneurysmal subarachnoid hemorrhage (upper panel); explaining a detrimental effect of hyperglycemia on clinical outcome (lower panel). DCI, delayed cerebral ischemia; SAH, subarachnoid hemorrhage.

Hyperglycemia and Clinical Outcome After Aneurysmal Subarachnoid Hemorrhage

Patients with hyperglycemia have an approximately threefold increased risk for poor outcome, and this seems unrelated to the different cutoff levels used to define hyperglycemia (Kruyt et al, 2009). The association between high levels of blood glucose and poor clinical outcome is more pronounced with persistent hyperglycemia than with hyperglycemia on admission (Badjatia et al, 2005; Frontera et al, 2006; Kruyt et al, 2008; Lanzino et al, 1993). A recent study showed that aSAH patients with persistent hyperglycemia are seven times more likely to have poor outcome than patients with normoglycemia, whereas in the same study, isolated hyperglycemic events throughout the clinical course were not predictive of poor outcome (McGirt et al, 2007).

How does Hyperglycemia Affect Outcome After Aneurysmal Subarachnoid Hemorrhage?

Although several studies found that high levels of blood glucose in the acute phase of aSAH are an independent risk factor for poor clinical outcome (Badjatia et al, 2005; Charpentier et al, 1999; Frontera et al, 2006; Kruyt et al, 2008), this does not prove causality of that relation. Elevated levels of admission blood glucose for example could constitute no more than a marker of SAH severity rather than a causative factor leading to secondary damage and consequently poorer clinical outcome. Indeed, high levels of admission glucose are associated with more severe SAH (Dorhout Mees et al, 2003; Kruyt et al, 2008). On the other hand, several experimental and imaging studies, as well as clinical observations, have highlighted mechanisms through which hyperglycemia may affect clinical outcome after aSAH (Figure 1, lower panel).

In critical illness in general, hyperglycemia on admission and during the clinical course is associated with various in-hospital complications such as respiratory failure, nosocomial infections, and impaired wound healing, all of which are contributors to poor outcome (Frontera et al, 2006; van den Berghe et al, 2001). Several trials, including trials in patients with aSAH (Bilotta et al, 2007) showed that IIT lowered these in-hospital complications (van den Berghe et al, 2005, 2001).

Another factor that could link hyperglycemia to poor outcome is DCI. The DCI occurs in approximately one third of aSAH patients, mostly between days 4 and 10 (Roos et al, 2000) and can progress to irreversible cerebral infarction with subsequent poor clinical outcome (Rosengart et al, 2007). Patients with hyperglycemia on admission or during the clinical course develop DCI and cerebral infarction more often than patients with normal blood glucose levels (Badjatia et al, 2005; Charpentier et al, 1999; Frontera et al, 2006; Juvela et al, 2005; Kruyt et al, 2008; Lanzino, 2005). The association between admission hyperglycemia and DCI was weaker than that of persistent hyperglycemia and DCI, and the association between admission glucose and DCI did not persist after multivariable assessment in several studies (Badjatia et al, 2005; Frontera et al, 2006; Juvela et al, 2005; Kruyt et al, 2008). The fact that aSAH patients with preexistent DM are at an increased risk of DCI compared with aSAH patients without preexistent DM lends further support of a link between abnormalities of glucose metabolism and DCI in aSAH patients (Dumont et al, 2009; Fergusen and Macdonald, 2007).

The cause of DCI in aSAH patients remains unclear, but various mechanisms have been proposed that may be influenced by hyperglycemia. One of these mechanisms is vasospasm, which is frequently seen in aSAH patients (Fergusen and Macdonald, 2007). In vitro and in vivo studies have linked hyperglycemia to vascular tone by inhibition of vasodilatation and by increasing vasoconstriction. Vasodilatation is predominantly mediated by endothelium-derived nitric oxide (Fleming and Busse, 2003; Vallance et al, 1989). In vitro studies show that hyperglycemia reduces the production of nitric oxide by increasing the activity of nicotinamide adenine dinucleotide phosphate (NADP) oxidase. In healthy individuals, glucose infusion for 6 hours reduces endothelium-dependent vasodilatation (Beckman et al, 2002; Williams et al, 1998). Moreover, hyperglycemia is associated with the formation of vasoconstrictive prostaglandins and increased eicosanoid production, both resulting in vasoconstriction (el-Kashef, 1996; Jawerbaum et al, 1995; Natarajan et al, 1993).

Although vasospasm is associated with the occurrence of DCI, it does not fully explain DCI (Dankbaar et al, 2009). Several other mechanisms, of which microthrombosis and inflammation are the most prominent, seem to contribute to DCI (Vergouwen et al, 2008). Hyperglycemia is closely linked to increased coagulation and decreased fibrinolysis, both of which enhance thrombin formation. In studies in healthy individuals, hyperglycemia stimulates coagulation by increasing platelet activation through thrombin–antithrombin complexes and the tissue factor pathway (Gentile et al, 2007; Rao et al, 1999; Stegenga et al, 2006; Vaidyula et al, 2006), and hyperinsulinemia decreases fibrinolytic activity by increasing plasminogen activator inhibitor (Festa et al, 1999; Meigs et al, 2000; Pandolfi et al, 2001; Stegenga et al, 2006).

Besides interference with coagulation and fibrinolysis, hyperglycemia is also associated with an increase in proinflammatory transcription factors and proinflammatory cytokines (Bemeur et al, 2007; Esposito et al, 2002; Garg et al, 2006; Martini and Kent, 2007). In aSAH patients, several studies have linked markers of increased inflammation to the development of DCI (Esposito et al, 2002; Hirashima et al, 1997; Osuka et al, 1998).

Once DCI is established in aSAH patients, the most imminent danger is that potentially reversible ischemic tissue progresses to irreversible infarcted tissue. Experimental and clinical imaging studies in ischemic stroke show that hyperglycemia is associated with this progression (Els et al, 2002; Parsons et al, 2002; Wagner et al, 1992).

Although restoration of blood flow to ischemic tissue is essential, reperfusion itself can also induce injury: so-called reperfusion injury (McCord, 1985). The mediators of reperfusion injury are inflammation and oxidative stress. Markers of inflammation are associated with the progression of cerebral ischemia to infarction (Chamorro and Hallenbeck, 2006; Wang et al, 2007) and, in experimental stroke, inhibition of the inflammatory response reduces infarct size (Arumugam et al, 2009). As outlined earlier, hyperglycemia increases the inflammatory response, and may therefore exacerbate reperfusion injury. The other mediator of reperfusion injury, oxidative stress, results from an imbalance between the production and neutralization of reactive oxygen species. Reactive oxygen species have been shown to increase neuronal death and infarct volume (Bemeur et al, 2005, 2007; Li et al, 2005; Muralikrishna and Hatcher, 2006; Suh et al, 2008). In experimental ischemic stroke, hyperglycemia increases the production of reactive oxygen species through the activation of protein kinase C and through increased NADP production, thus promoting oxidative stress.

In addition to increased reperfusion injury, hyperglycemia also promotes anaerobic glycolysis leading to the accumulation of lactic acid and a derangement in pH homeostasis. Both these processes have been proposed to contribute to increased brain injury (Anderson et al, 1999; Katsura et al, 1992; Siesjo, 1988). In support of a detrimental role of lactic acid is the finding that in patients with cerebral ischemia, hyperglycemia correlates with both an increased lactate production and with the progression from ischemic to infarcted tissue (Parsons et al, 2002).

In conclusion, a causal relation between hyperglycemia and poor outcome in aSAH patients remains elusive, but in the sequence of events that occur after aSAH, hyperglycemia may exert a detrimental effect by increasing secondary complications such as infection and cerebral ischemia, as well as by facilitating the progression from ischemia to irreversible infarction. Besides lowering of blood glucose levels with insulin, a more mechanistic approach with interventions directly aimed at the restoration of glucose homeostasis have potential clinical relevance. For example, pharmacological neutralization of cytokines was shown to revert insulin resistance (Xu et al, 2008), and inhibition of cortisol production prevented hyperglycemic aggravation of ischemic neuronal damage (Payne et al, 2003). These findings, however, are experimental and should not be extrapolated to the clinical setting.

Glucose Lowering Therapy

Studies in non-Aneurysmal Subarachnoid Hemorrhage Patients

Before addressing glucose lowering therapy in aSAH patients, we first summarize current insights on this topic in other groups of critically ill patients because this provides relevant background information.

In 2001, intensive insulin therapy (IIT) was implemented worldwide in intensive care unit (ICU) facilities after a landmark trial from Leuven demonstrated its clinical benefit in a surgical ICU (van den Berghe et al, 2001, 2006).

Several later trials could not confirm the previous positive findings (Annane et al, 2010; Brunkhorst et al, 2008; Finfer et al, 2009). In one of these trials, IIT was even associated with an increased risk of severe hypoglycemia (glucose < 2.2.mmol/L) and subsequent poor clinical outcome (Finfer et al, 2009). It remains unclear why these recent and earlier trials show conflicting results. One possible explanation is that in the time frame that separated these trials, the standards for hyperglycemia management in ‘regular care’ are more rigorous, thus decreasing the potential contrast with an IIT group in trials. Meanwhile, IIT is still recommended for patients admitted to an ICU (Griesdale et al, 2009), but the latter trials have emphasized the important drawback of IIT namely increased incidence of hypoglycemia.

In stroke other than aSAH, the UK Glucose Insulin in Stroke Trial failed to show a clinical benefit from glycemic control on clinical outcome (Gray et al, 2007). This trial, however, was stopped prematurely because of slow enrolment. Other limitations of the trial were a relatively short duration of treatment (24 hours) and a small contrast in mean glucose levels (0.57 mmol/L) between the intervention and the control group.

Studies in Aneurysmal Subarachnoid Hemorrhage Patients

We performed a systematic literature search on glucose lowering treatment in aSAH patients. MEDLINE was searched on published studies from 1966 to February 2010 written in English, German, French, or Spanish. We used the medical subject headings (MeSH) and search terms ‘blood glucose’ and ‘subarachnoid hemorrhage’ truncated text words ‘hyperglyc(a)emia,’ ‘glucose,’ ‘subarachnoid,’ ‘SAH,’ ‘h(a)emorrhage,’ and ‘bleeding’ in different combinations. Studies describing a consecutive series of aSAH patients who were treated with IIT and who reported glucose levels during IIT (i.e., not only admission glucose levels) could be included. When an article complied with the inclusion criteria but lacked information on parameters of hypoglycemia, we approached the authors to obtain these data. We hand searched the bibliographies of all included articles and abstract books of the European and American stroke congresses held from January 2008 to October 2009. The MEDLINE search yielded 92 articles. Most articles were excluded because patients were not given IIT or because glucose levels during the clinical course were not reported (58). Other reasons for exclusion were nonconsecutive series (20), same population described (2), and non-aSAH patients described (6).

No additional relevant studies were found by searching the bibliographies or abstract books. We identified six studies (listed in Table 1); five cohort studies, of which two compared glucose levels before and after the introduction of IIT and one small randomized controlled trial (Bell and Strong, 2005; Bilotta et al, 2007; Latorre et al, 2009; Naidech et al, 2009; Thiele et al, 2009).

Table 1

Studies reporting on intensive insulin therapy in SAH patients

Authors	Study type	N	Intervention target (mmol/L)	Glycemic control		Clinical outcome

				Glycemic control parameters	Hypoglycemia parameters
Bell and Strong (2005)	Pilot, uncontrolled	55	5.0–7.0	75% Assessments < 7.0	0.9% Assessments < 3.5	—
Bilotta et al (2007)	Randomized controlled trial	38	Controls: 4.4–12.2	Mean glucose: 7.9^a	3.5% Assessments < 4.4	6 months clinical outcome and vasospasm: no difference
		40	IIT: 4.4–6.6	Mean glucose: 5.0^a	10.5% Assessments < 4.4	Infection rate decreased with IIT (42–27%)
Latorre et al (2009)	Sequential comparison^b	166	Preprotocol: < 11.1	Mean glucose: 8.9 (± 1.7)	2.4% of Assessments < 3.9	3–6 months poor outcome decreased with IIT (40.2–28.3%)
		166	IIT: 4.4–7.8	Mean glucose: 8.0 (± 0.9)	12.7% of Assessments < 3.9
Thiele et al (2009)	Sequential comparison^b	343	Preprotocol: NR	Median glucose: 6.7 (6.2–7.4)	1.5% Patients ≥1 episode with glucose < 3.3	No effect on overall in-hospital mortality with IIT
		491	IIT: 5.0–6.7	Median glucose: 6.5 (6.0–6.9)	7.1% Patients ≥1 episode with glucose < 3.3
Schlenk et al (2009)	Prospective cohort	178	IIT: 4.4–7.8	Mean glucose: 7.5	—	—
Naidech et al (2010)	Prospective cohort	172	IIT: 4.4–6.1	Mean glucose: 6.8 (± 0.8)	Mean lowest glucose: 4.7 One serious hypoglycemic event (< 2.2)	—

IIT, intensive insulin therapy; NR, not reported (interquartile range); SAH, subarachnoid hemorrhage.

These data were provided by the authors on request.

This means a comparison between a cohort before and a cohort after the introduction of IIT.

In all identified studies, patients were admitted to an ICU. Glucose levels targets varied somewhat between the studies with upper limits of glucose levels ranging from 6 to 7.8 mmol/L and lower limits ranging from 4.4 to 5.0 mmol/L. The cutoff level used to define hypoglycemia varied between studies (3.5 to 4.4 mmol/L). None of the studies reported neurologic deterioration during hypoglycemia; however, the warning symptoms of hypoglycemia might be less clear in patients with aSAH than in other patients, as these symptoms are similar to some stroke comorbidities (Hemmen et al, 2008).

One uncontrolled pilot study showed that IIT was feasible but was accompanied by hypoglycemic episodes (Bell and Strong, 2005). In the only randomized trial that was designed to test the applicability of IIT, 78 patients were enrolled. The IIT reduced the mean glucose from 8.0 to 5.0 mmol/L, but increased hypoglycemic episodes from 3.5% to 10.5% (Bilotta et al, 2007). The IIT reduced the infection rate from 42% to 27% (P < 0.001), but did not improve clinical outcome, although the number of included patients was too small to reliably address this. Currently, a phase II safety study with hypoglycemia as primary outcome by the same research group aims to randomize 800 neurosurgical ICU patients between IIT and regular care (Bilotta, 2010). We identified two sequential observation studies comparing clinical outcome in aSAH patients before and after the introduction of IIT (Latorre et al, 2009; Thiele et al, 2009). The first study (total n = 332) used a prospective database, with retrospective review of patient characteristics and clinical outcome data (Latorre et al, 2009). After the introduction of IIT, mean blood glucose levels decreased from 8.9 to 8.0 mmol/L, whereas the percentage of glucose measurements that fell in the hypoglycemic range increased from 2.4% to 12.7%. At baseline, IIT-treated patients more often had hypertension, DM, and cerebral infarction. Still, clinical outcome was better in IIT-treated patients compared with non-IIT-treated patients (odds ratio for poor outcome, 0.25; 95% confidence interval, 0.08 to 0.80), although this difference was not significant after adjusting for temporal trend, that is taking into account that other variables than IIT could improve clinical outcome. The second study that compared clinical outcome in aSAH patients before and after the introduction of IIT was larger (N = 834), but clinical data were collected retrospectively (Thiele et al, 2009). The IIT achieved only a small reduction in the mean glucose (0.2 mmol/L) and glucose measurements that fell in the hypoglycemic range, increased from 1.5% to 7.1%. In this study, IIT was not accompanied by a reduction of in-hospital mortality. However, the study lacked data on baseline aSAH severity, whereas patients receiving IIT more often had intraventricular or parenchymal hematoma, which suggests more severe aSAH in this group.

In conclusion, currently there is no evidence that hyperglycemia in aSAH patients should be lowered actively. Moreover, IIT is accompanied by an increase in hypoglycemic episodes, which should raise concerns about the safety of this therapy.

Risk of Intensive Insulin Therapy: Hypoglycemia

As noted earlier, IIT is invariably accompanied by hypoglycemic episodes, which is posing a potential risk to aSAH patients subjected to this therapy. The brain relies on the continuous delivery of glucose through the blood to maintain normal metabolic function. Moreover, various studies indicate that under conditions of acute brain injury, glucose utilization is increased (Andersen and Marmarou, 1992; Bergsneider et al, 1997; Oddo et al, 2008). Thus, it is conceivable that hypoglycemia on top of preexisting cerebral damage and the increased glucose utilization is even more detrimental than for the healthy brain (double-hit theory) (de Courten-Meyers et al, 1994). Besides simple deprivation of energy, another interesting explanation for hypoglycemia to be detrimental to the brain is the occurrence of cortical spreading depression (CSD), a slowly moving wave that leads to intracellular calcium overload and depression of synaptic activity (Leão, 1944). Such depolarization waves occur frequently in patients with aSAH (Dreier et al, 2009; Strong et al, 2000). In focal ischemia of nonhuman primates, even mild hypoglycemia promoted the occurrence of CSDs (Dreier et al, 2009; Strong et al, 2000). More recently, in a patient with aSAH, a severe cluster of CSDs was associated with (IIT induced) hypoglycemia (Dreier et al, 2009; Strong et al, 2000). Interestingly, CSD can by itself also lead to the depletion of extracellular cerebral glucose levels thereby further jeopardizing brain tissue (Hashemi et al, 2009). Although IIT was never proven to be beneficial for neurologic critically ill patients, various IIT protocols, often with different glycemic targets, are being used on ICU's worldwide also for this particular patient group (see Table 1). This has driven various research groups to investigate the metabolic consequences of IIT in patients with brain injury with the use of microdialysis (Sarrafzadeh et al, 2004; Schlenk et al, 2008b, 2009; Vespa et al, 2006; Vespa, 2006). This technique, for which a microcatheter is inserted into the brain parenchyma, allows in vitro monitoring of regional brain metabolites such as glucose, lactate, glutamate, and glycerol (Ungerstedt, 1991). Observations from these studies increase our understanding of regional metabolic changes in response to changes in serum blood glucose levels, and potentially contribute to rational glycemic targets that should be aimed for with IIT. Various studies have shown that brain injury, including aSAH, is accompanied bymetabolic derangements that indicate distress such as increased glutamate, glycerol, and lactate/pyruvate ratio (Oddo et al, 2008; Schlenk et al, 2008b; Vespa et al, 2006). In patients with traumatic brain injury, IIT-induced low levels of blood glucose were associated with reduced cerebral glucose availability and increased prevalence of metabolic distress (Oddo et al, 2008; Vespa et al, 2006). For patients with aSAH, this association seems less clear. Various studies have shown that levels of systemic glucose do not necessarily correlate with cerebral glucose levels after aSAH (Schlenk et al, 2008b, 2009) although in the largest study, including 178 aSAH patients, it was shown that when mean inpatient blood glucose levels exceeded 7.8 mmol/L, cerebral glucose levels also increased (Schlenk et al, 2009). The same group also reported that extracellular cerebral glucose levels decreased 3 hours after initiation of IIT despite stable blood glucose levels (Schlenk et al, 2008a). Moreover, episodes of low cerebral glucose occurred somewhat more frequent in IIT-treated patients than in patients not treated with insulin (Schlenk et al, 2008a, b ). Unfortunately, in these studies no episodes of serum hypoglycemia were monitored, which could have provided insight into cerebral metabolites during such condition. Recently, another group reported that abrupt reductions of blood glucose of > 25% rather than an absolute decrease in blood glucose levels were associated with brain metabolic crisis (defined as an increased lactate/pyruvate ratio) occurring hours thereafter (Helbok et al, 2010). Although the studies that used microdialysis are generally small, often retrospective and without randomization for patients with or without IIT, they do emphasize that IIT is not without risk. In this respect, especially the observations that low levels of serum glucose are sometimes also accompanied by low extracellular glucose levels and that abrupt reductions of glucose levels are accompanied by brain metabolic crisis should warrant caution in executing IIT in these patients.

Conclusions and Future Directions

For a long time, hyperglycemia was thought to be an adaptive beneficial response to critical illness to provide those organs that predominantly rely on glucose as metabolic substrate such as the brain. With the publication of the landmark Leuven trials, however, this concept has changed dramatically and IIT was implemented worldwide for all kinds of critically ill patients, including patients with brain injury. It is important, however, to realize that today IIT was proven only in monocenter studies and for a subgroup of critically ill patients. In addition, more recently a large multicenter study could not prove a beneficial effect from IIT and IIT was even associated with an increased risk of severe hypoglycemia and subsequent poor clinical outcome (Finfer et al, 2009). Therefore, although hyperglycemia, especially if persistent during the clinical course, clearly predicts poor clinical outcome in aSAH patients, care should be taken in extrapolating previous positive data to aSAH patients. The most recent guidelines for the treatment of aSAH state that it is imperative to avoid hyperglycemia (Bederson et al, 2009). However, it is unclear which glucose levels should be targeted and how this has to be accomplished. Only a large-scale randomized controlled trial investigating the clinical benefit of IIT in aSAH patients will be able to resolve this issue.

Before initiating such a trial, however, it is important to improve glycemic control in phase II studies with special reference to safety. In these studies, focus should be not only on the lowering of glucose levels, but, and perhaps even more so, on the prevention of hypoglycemia related to this therapy. As for the question which glucose targets should be aimed at, there is no unambiguous answer. On the one hand, when IIT does not achieve a substantial lowering of blood glucose levels compared with standard ICU therapy, this treatment is not likely to result in a clinical benefit (Gray et al, 2007; Griesdale et al, 2009). On the other hand, the most recent trials in non-aSAH patients have shown that IIT targeting blood glucose levels in a low physiological range (4.4 to 6.1 mmol/L) is associated with serious hypoglycemic episodes (glucose < 2.2 mmol/L) and subsequent worse clinical outcome (Brunkhorst et al, 2008; Finfer et al, 2009). A recent cohort study in aSAH patients emphasized this, by demonstrating that not high, but IIT-induced nadir levels of blood glucose, were associated with poor clinical outcome (Naidech et al, 2009). Possibly, as in other critically ill patients, there is a U-shaped glycemia-mortality risk curve in aSAH patients with both low and high blood glucose levels relating to worse outcome (van den Berghe et al, 2009). Ideally, glucose levels in the flat part of this curve should be targeted. From the studies we identified, however, strict glucose control in aSAH patients seems difficult to establish without a risk of (serious) hypoglycemia. The definition of an optimal and safe glycemic target range is as yet unclear and may not be uniform among patients and even vary for individual patients at various time points during the clinical course. Future studies that monitor brain metabolites with microdialysis and CSDs with electrocorticography could perhaps facilitate the identification of a safe glycemic range from a brain's metabolic perspective (Vespa, 2008), although this would not be easy to implement in clinical practice, as currently most ruptured aneurysms are treated with endovascular coiling, and the occurrence of a hydrocephalus, the other intervention providing the possibility to insert a microdialysis catheter, occurs in only 30% of patients (Germanwala et al, 2010).

All studies we identified on IIT were performed in the ICU setting. Patients with clinically less severe aSAH are sometimes admitted to a stroke unit. In contrast to an ICU, a stroke unit often lacks the highly intensive treatment facilities available on the ICU. For instance, the lack of direct access to frequent arterial blood glucose monitoring and fewer personnel per patient to execute laborious treatment algorithms could render glycemic control even more challenging than on the ICU facility.

Considering this, if decided to actively lower hyperglycemia in aSAH patients as is recommended by the guidelines, the best advice seems to institute a multidisciplinary team, including stroke and diabetes experts to facilitate the implementation of glucose lowering protocols with the aim to lower blood glucose levels only if this can be performed without subsequent hypoglycemia. Such a protocol should probably include close monitoring of blood glucose levels with a high rate of insulin adjustments (i.e., every 1 or 2 hours). Continuous glucose monitoring devices that are now becoming available and the use of computerized treatment algorithms have the potential to facilitate this, but the safety of these devices will have to be investigated first (Vriesendorp et al, 2005).

In conclusion, target levels of blood glucose will remain arbitrary until a randomized control trial has investigated the clinical benefit of IIT. Before such a trial can start, focus should be on how IIT can be improved both in terms of efficacy but perhaps more important in terms of safety.

Search strategy and selection criteria

References for this review were identified by searches of PubMed from 1966 until February 2010 with the terms ‘blood glucose’ and ‘subarachnoid hemorrhage’ truncated text words ‘hyperglyc(a)emia,’ ‘glucose,’ ‘subarachnoid,’ ‘SAH,’ ‘h(a)emorrhage,’ and ‘bleeding.’ Articles were also identified through searches of the authors' own files. Only papers published in English, German, French, or Spanish were reviewed.

Footnotes

The authors declare no conflict of interest.

References

Adams

Jr Putman

Kassell

Torner

(1984) Prevalence of diabetes mellitus among patients with subarachnoid hemorrhage. Arch Neurol 41:1033–5

Andersen

Marmarou

(1992) Post-traumatic selective stimulation of glycolysis. Brain Res 585:184–9

Anderson

Tan

Martin

Meyer

(1999) Effects of glucose and PaO2 modulation on cortical intracellular acidosis, NADH redox state, and infarction in the ischemic penumbra. Stroke 30:160–70

Annane

Cariou

Maxime

Azoulay

D'Honneur

Timsit

Cohen

Wolf

Fartoukh

Adrie

Santre

Bollaert

Mathonet

Amathieu

Tabah

Clec'h

Mayaud

Lejeune

Chevret

(2010) Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 303:341–8

Arumugam

Woodruff

Lathia

Selvaraj

Mattson

Taylor

(2009) Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 158:1074–89

Badjatia

Topcuoglu

Buonanno

Smith

Nogueira

Rordorf

Carter

Ogilvy

Singhal

(2005) Relationship between hyperglycemia and symptomatic vasospasm after subarachnoid hemorrhage. Crit Care Med 33:1603–9

Barth

Albuszies

Baumgart

Matejovic

Wachter

Vogt

Radermacher

Calzia

(2007) Glucose metabolism and catecholamines. Crit Care Med 35:S508–18

Beckman

Goldfine

Gordon

Garrett

Creager

(2002) Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90:107–11

Bederson

Connolly

Jr Batjer

Dacey

Dion

Diringer

Duldner

Jr Harbaugh

Patel

Rosenwasser

(2009) Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 40:994–1025

10.

Bell

Strong

(2005) Glucose/insulin infusions in the treatment of subarachnoid haemorrhage: a feasibility study. Br J Neurosurg 19:21–4

11.

Bemeur

Ste-Marie

Desjardins

Vachon

Butterworth

Hazell

Montgomery

(2005) Dehydroascorbic acid normalizes several markers of oxidative stress and inflammation in acute hyperglycemic focal cerebral ischemia in the rat. Neurochem Int 46:399–407

12.

Bemeur

Ste-Marie

Montgomery

(2007) Increased oxidative stress during hyperglycemic cerebral ischemia. Neurochem Int 50:890–904

13.

Bergsneider

Hovda

Shalmon

Kelly

Vespa

Martin

Phelps

McArthur

Caron

Kraus

Becker

(1997) Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. J Neurosurg 86:241–51

14.

Bilotta Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy (2010). http://www.clinicaltrials.gov accessed May 2010

15.

Bilotta

Spinelli

Giovannini

Doronzio

Delfini

Rosa

(2007) The effect of intensive insulin therapy on infection rate, vasospasm, neurologic outcome, and mortality in neurointensive care unit after intracranial aneurysm clipping in patients with acute subarachnoid hemorrhage: a randomized prospective pilot trial. J Neurosurg Anesthesiol 19:156–60

16.

Brunkhorst

Engel

Bloos

Meier-Hellmann

Ragaller

Weiler

Moerer

Gruendling

Oppert

Grond

Olthoff

Jaschinski

John

Rossaint

Welte

Schaefer

Kern

Kuhnt

Kiehntopf

Hartog

Natanson

Loeffler

Reinhart

(2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–39

17.

Capes

Hunt

Malmberg

Pathak

Gerstein

(2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426–32

18.

Chamorro

Hallenbeck

(2006) The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 37:291–3

19.

Charpentier

Audibert

Guillemin

Civit

Ducrocq

Bracard

Hepner

Picard

Laxenaire

(1999) Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurysmal subarachnoid hemorrhage. Stroke 30:1402–8

20.

Crompton

(1963) Hypothalamic lesions following the rupture of cerebral berry aneurysms. Brain 86:301–14

21.

Dankbaar

Rijsdijk

van der Schaaf

Velthuis

Wermer

Rinkel

(2009) Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neuroradiology 51:813–9

22.

de Courten-Meyers

Kleinholz

Wagner

Myers

(1994) Normoglycemia (not hypoglycemia) optimizes outcome from middle cerebral artery occlusion. J Cereb Blood Flow Metab 14:227–36

23.

Dorhout Mees

van Dijk

Algra

Kempink

Rinkel

(2003) Glucose levels and outcome after subarachnoid hemorrhage. Neurology 61:1132–3

24.

Dreier

Major

Manning

Woitzik

Drenckhahn

Steinbrink

Tolias

Oliveira-Ferreira

Fabricius

Hartings

Vajkoczy

Lauritzen

Dirnagl

Bohner

Strong

(2009) Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 132:1866–81

25.

Dumont

Rughani

Silver

Tranmer

(2009) Diabetes mellitus increases risk of vasospasm following aneurysmal subarachnoid hemorrhage independent of glycemic control. Neurocrit Care 11:183–9

26.

el-Kashef

(1996) Hyperglycemia increased the responsiveness of isolated rabbit's pulmonary arterial rings to serotonin. Pharmacology 53:151–9

27.

Els

Klisch

Orszagh

Hetzel

Schulte-Monting

Schumacher

Lucking

(2002) Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. Cerebrovasc Dis 13:89–94

28.

Esposito

Nappo

Marfella

Giugliano

Ciotola

Quagliaro

Ceriello

Giugliano

(2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067–72

29.

Feigin

Rinkel

Lawes

Algra

Bennett

van

Anderson

(2005) Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke 36:2773–80

30.

Fergusen

Macdonald

(2007) Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 60:658–67

31.

Festa

D'Agostino

Jr Mykkanen

Tracy

Zaccaro

Hales

Haffner

(1999) Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19:562–8

32.

Finfer

Chittock

Blair

Foster

Dhingra

Bellomo

Cook

Dodek

Henderson

Hebert

Heritier

Heyland

McArthur

McDonald

Mitchell

Myburgh

Norton

Potter

Robinson

Ronco

(2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1283–97

33.

Fleming

Busse

(2003) Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284:R1–12

34.

Frontera

Fernandez

Claassen

Schmidt

Schumacher

Wartenberg

Temes

Parra

Ostapkovich

Mayer

(2006) Hyperglycemia after SAH: predictors, associated complications, and impact on outcome. Stroke 37:199–203

35.

Garg

Chaudhuri

Munschauer

Dandona

(2006) Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke 37:267–73

36.

Gauna

van den Berghe

van der Lely

(2005) Pituitary function during severe and life-threatening illnesses. Pituitary 8:213–7

37.

Gearhart

Parbhoo

(2006) Hyperglycemia in the critically ill patient. AACN Clin Issues 17:50–5

38.

Gentile

Vaidyula

Kanamalla

DeAngelis

Gaughan

Rao

(2007) Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia. Thromb Haemost 98:1007–13

39.

Germanwala

Huang

Tamargo

(2010) Hydrocephalus after aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am 21:263–70

40.

Gray

Hildreth

Sandercock

O'Connell

Johnston

Cartlidge

Bamford

James

Alberti

(2007) Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 6:397–406

41.

Gray

Scott

French

Alberti

O'Connell

(2004) Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing 33:71–7

42.

Griesdale

de Souza

van Dam

Heyland

Cook

Malhotra

Dhaliwal

Henderson

Chittock

Finfer

Talmor

(2009) Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 180:821–7

43.

Hashemi

Bhatia

Nakamura

Dreier

Graf

Strong

Boutelle

(2009) Persisting depletion of brain glucose following cortical spreading depression, despite apparent hyperaemia: evidence for risk of an adverse effect of Leao's spreading depression. J Cereb Blood Flow Metab 29:166–75

44.

Helbok

Schmidt

Kurtz

Hanafy

Fernandez

Stuart

Presciutti

Ostapkovich

Connolly

Lee

Badjatia

Mayer

Claassen

(2010) Systemic glucose and brain energy metabolism after subarachnoid hemorrhage. Neurocrit Care 12:317–23

45.

Hemmen

Meyer

McClean

Lyden

(2008) Identification of nonischemic stroke mimics among 411 code strokes at the University of California, San Diego, Stroke Center. J Stroke Cerebrovasc Dis 17:23–5

46.

Hendryk

Jarzab

Josko

(2004) Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett 25:141–7

47.

Hirashima

Nakamura

Endo

Kuwayama

Naruse

Takaku

(1997) Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res 22:1249–55

48.

Hotamisligil

Spiegelman

(1994) Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43:1271–8

49.

Hunt

Ivy

(2002) Epinephrine inhibits insulin-stimulated muscle glucose transport. J Appl Physiol 93:1638–43

50.

Jawerbaum

Franchi

Gonzalez

Novaro

de Gimeno

(1995) Hyperglycemia promotes elevated generation of TXA2 in isolated rat uteri. Prostaglandins 50:47–56

51.

Juvela

Siironen

Kuhmonen

(2005) Hyperglycemia, excess weight, and history of hypertension as risk factors for poor outcome and cerebral infarction after aneurysmal subarachnoid hemorrhage. J Neurosurg 102:998–1003

52.

Katsura

Asplund

Ekholm

Siesjo

(1992) Extra- and intracellular pH in the brain during ischaemia, related to tissue lactate content in normo- and hypercapnic rats. Eur J Neurosci 4:166–76

53.

Kernan

Viscoli

Inzucchi

Brass

Bravata

Shulman

McVeety

(2005) Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke. Arch Intern Med 165:227–33

54.

Klose

Brennum

Poulsgaard

Kosteljanetz

Wagner

Feldt-Rasmussen

(2010) Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage. Clin Endocrinol (Oxf); 23 January 2010 [e-pub ahead of print] PMID:20105184

55.

Kruyt

Biessels

de Haan

Vermeulen

Rinkel

Coert

Roos

(2009) Hyperglycemia and clinical outcome in aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke 40:e424–30

56.

Kruyt

Roos

Dorhout Mees

van den Bergh

Algra

Rinkel

Biessels

(2008) High mean fasting glucose levels independently predict poor outcome and delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 79:1382–5

57.

Lanzino

(2005) Plasma glucose levels and outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 102:974–5

58.

Lanzino

Kassell

Germanson

Truskowski

Alves

(1993) Plasma glucose levels and outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 79:885–91

59.

Latorre

Chou

Nogueira

Singhal

Carter

Ogilvy

Rordorf

(2009) Effective glycemic control with aggressive hyperglycemia management is associated with improved outcome in aneurysmal subarachnoid hemorrhage. Stroke 40:1644–52

60.

Leão

(1944) Spreading depression of activity in cerebral cortex. J Neurophysiol 7:359–90

61.

Zheng

Carmichael

(2005) Increased oxidative protein and DNA damage but decreased stress response in the aged brain following experimental stroke. Neurobiol Dis 18:432–40

62.

Martini

Kent

(2007) Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab 27:435–51

63.

McCord

(1985) Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312:159–63

64.

McGirt

Woodworth

Ali

Than

Tamargo

Clatterbuck

(2007) Persistent perioperative hyperglycemia as an independent predictor of poor outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 107:1080–5

65.

Meigs

Mittleman

Nathan

Tofler

Singer

Murphy-Sheehy

Lipinska

D'Agostino

Wilson

(2000) Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283:221–8

66.

Muralikrishna

Hatcher

(2006) Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med 40:376–87

67.

Naidech

Levasseur

Liebling

Garg

Shapiro

Ault

Afifi

Batjer

(2010) Moderate hypoglycemia is associated with vasospasm, cerebral infarction, and 3-month disability after subarachnoid hemorrhage. Neurocrit Care 12:181–7

68.

Naredi

Lambert

Eden

Zall

Runnerstam

Rydenhag

Friberg

(2000) Increased sympathetic nervous activity in patients with nontraumatic subarachnoid hemorrhage. Stroke 31:901–6

69.

Natarajan

Rossi

Gonzales

Lanting

Nadler

(1993) Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc Natl Acad Sci USA 90:4947–51

70.

Nieuwkamp

Setz

Algra

Linn

de Rooij

Rinkel

(2009) Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol 8:635–42

71.

Obici

Zhang

Karkanias

Rossetti

(2002) Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8:1376–82

72.

Oddo

Schmidt

Carrera

Badjatia

Connolly

Presciutti

Ostapkovich

Levine

Mayer

(2008) Impact of tight glycemic control on cerebral glucose metabolism after severe brain injury: a microdialysis study. Crit Care Med 36:3233–8

73.

Osuka

Suzuki

Tanazawa

Hattori

Yamamoto

Takayasu

Shibuya

Yoshida

(1998) Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien) 140:943–51

74.

Pandolfi

Giaccari

Cilli

Alberta

Morviducci

De Filippis

Buongiorno

Pellegrini

Capani

Consoli

(2001) Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol 38:71–6

75.

Parsons

Barber

Desmond

Baird

Darby

Byrnes

Tress

Davis

(2002) Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 52:20–8

76.

Payne

Tseng

Schurr

(2003) The glucose paradox of cerebral ischemia: evidence for corticosterone involvement. Brain Res 971:9–17

77.

Plomgaard

Bouzakri

Krogh-Madsen

Mittendorfer

Zierath

Pedersen

(2005) Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 54:2939–45

78.

Rao

Chouhan

Chen

Sun

Boden

(1999) Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 48:1156–61

79.

Rask-Madsen

Dominguez

Ihlemann

Hermann

Kober

Torp-Pedersen

(2003) Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108:1815–21

80.

Roos

de Haan

Beenen

Groen

Albrecht

Vermeulen

(2000) Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry 68:337–41

81.

Rosengart

Schultheiss

Tolentino

Macdonald

(2007) Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke 38:2315–21

82.

Sarrafzadeh

Haux

Kuchler

Lanksch

Unterberg

(2004) Poor-grade aneurysmal subarachnoid hemorrhage: relationship of cerebral metabolism to outcome. J Neurosurg 100:400–6

83.

Schlenk

Graetz

Nagel

Schmidt

Sarrafzadeh

(2008a) Insulin-related decrease in cerebral glucose despite normoglycemia in aneurysmal subarachnoid hemorrhage. Crit Care 12:R9

84.

Schlenk

Nagel

Graetz

Sarrafzadeh

(2008b) Hyperglycemia and cerebral glucose in aneurysmal subarachnoid hemorrhage. Intensive Care Med 34:1200–7

85.

Schlenk

Vajkoczy

Sarrafzadeh

(2009) Inpatient hyperglycemia following aneurysmal subarachnoid hemorrhage: relation to cerebral metabolism and outcome. Neurocrit Care 11:56–63

86.

Schneider

Kreitschmann-Andermahr

Ghigo

Stalla

Agha

(2007) Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA 298:1429–38

87.

Schwartz

Porte

Jr (2005) Diabetes, obesity, and the brain. Science 307:375–9

88.

Seematter

Binnert

Martin

Tappy

(2004) Relationship between stress, inflammation and metabolism. Curr Opin Clin Nutr Metab Care 7:169–73

89.

Siesjo

(1988) Acidosis and ischemic brain damage. Neurochem Pathol 9:31–88

90.

Stegenga

van der Crabben

Levi

de Vos

Tanck

Sauerwein

van der Poll

(2006) Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 55:1807–12

91.

Strong

Smith

Whittington

Meldrum

Parsons

Krupinski

Hunter

Patel

Robertson

(2000) Factors influencing the frequency of fluorescence transients as markers of peri-infarct depolarizations in focal cerebral ischemia. Stroke 31:214–22

92.

Suh

Shin

Van Hoecke

Brennan

Yenari

Swanson

(2008) Glucose and NADPH oxidase drive neuronal superoxide formation in stroke. Ann Neurol 64:654–63

93.

Thiele

Pouratian

Zuo

Scalzo

Dobbs

Dumont

Kassell

Nemergut

(2009) Strict glucose control does not affect mortality after aneurysmal subarachnoid hemorrhage. Anesthesiology 110:603–10

94.

Ungerstedt

(1991) Microdialysis–principles and applications for studies in animals and man. J Intern Med 230:365–73

95.

Vaidyula

Rao

Mozzoli

Homko

Cheung

Boden

(2006) Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 55:202–8

96.

Vallance

Collier

Moncada

(1989) Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2:997–1000

97.

van den Berghe

Schetz

Vlasselaers

Hermans

Wilmer

Bouillon

Mesotten

(2009) Clinical review: intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J Clin Endocrinol Metab 94:3163–70

98.

van den Berghe

Schoonheydt

Becx

Bruyninckx

Wouters

(2005) Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 64:1348–53

99.

van den Berghe

Wilmer

Hermans

Meersseman

Wouters

Milants

Van Wijngaerden

Bobbaers

Bouillon

(2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354:449–61

100.

van den Berghe

Wouters

Weekers

Verwaest

Bruyninckx

Schetz

Vlasselaers

Ferdinande

Lauwers

Bouillon

(2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–67

101.

van Gijn

Kerr

Rinkel

(2007) Subarachnoid haemorrhage. Lancet 369:306–18

102.

Vancheri

Curcio

Burgio

Salvaggio

Gruttadauria

Lunetta

Dovico

Alletto

(2005) Impaired glucose metabolism in patients with acute stroke and no previous diagnosis of diabetes mellitus. QJM 98:871–8

103.

Vergouwen

van

de Haan

Kruyt

Vermeulen

Roos

(2010) Increased cortisol levels are associated with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neurocrit Care 12:342–5

104.

Vergouwen

Vermeulen

Coert

Stroes

Roos

(2008) Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 28:1761–70

105.

Vespa

Boonyaputthikul

McArthur

Miller

Etchepare

Bergsneider

Glenn

Martin

Hovda

(2006) Intensive insulin therapy reduces microdialysis glucose values without altering glucose utilization or improving the lactate/pyruvate ratio after traumatic brain injury. Crit Care Med 34:850–6

106.

Vespa

(2006) The implications of cerebral ischemia and metabolic dysfunction for treatment strategies in neurointensive care. Curr Opin Crit Care 12:119–23

107.

Vespa

(2008) Intensive glycemic control in traumatic brain injury: what is the ideal glucose range? Crit Care 12:175

108.

Vriesendorp

DeVries

Holleman

Dzoljic

Hoekstra

(2005) The use of two continuous glucose sensors during and after surgery. Diabetes Technol Ther 7:315–22

109.

Wagner

Kleinholz

de Court

Myers

(1992) Hyperglycemic versus normoglycemic stroke: topography of brain metabolites, intracellular pH, and infarct size. J Cereb Blood Flow Metab 12:213–22

110.

Wang

Tang

Yenari

(2007) The inflammatory response in stroke. J Neuroimmunol 184:53–68

111.

Williams

Goldfine

Timimi

Ting

Roddy

Simonson

Creager

(1998) Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695–701

112.

Kim

Zhao

Zhai

Kokorina

Wang

Messina

(2008) Trauma and hemorrhage-induced acute hepatic insulin resistance: dominant role of tumor necrosis factor-alpha. Endocrinology 149:2369–82

Hyperglycemia in Aneurysmal Subarachnoid Hemorrhage: A Potentially Modifiable Risk Factor for Poor Outcome

Abstract

Keywords

Introduction

Mechanisms Leading to Hyperglycemia After Aneurysmal Subarachnoid Hemorrhage

Hyperglycemia and Clinical Outcome After Aneurysmal Subarachnoid Hemorrhage

How does Hyperglycemia Affect Outcome After Aneurysmal Subarachnoid Hemorrhage?

Glucose Lowering Therapy

Studies in non-Aneurysmal Subarachnoid Hemorrhage Patients

Studies in Aneurysmal Subarachnoid Hemorrhage Patients

Risk of Intensive Insulin Therapy: Hypoglycemia

Conclusions and Future Directions

Search strategy and selection criteria

Footnotes

References